Quantitative global phosphotyrosine proteomics of two mouse models of hypertrophic cardiomyopathy reveals that tyrosine kinase inhibitors may be a future therapeutic approach for treating hypertrophic cardiomyopathy.
- Mingguo Xu
- Kevin C. Bermea
- Genaro A. Ramirez-Correa